Shots:
- The CHMP has recommended to Voranigo for treating patients (age: ≥12yrs.; wt≥ 40kg) with Gr2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation post-surgery but do not currently require radiotherapy or CT; anticipated EC decision in all 30 EEA states
- The CHMP opinion is based on the global P-III (INDIGO) trial (N=331), which included VORANIGO (n=168) or PBO (n=163). Among them, oligodendroglioma (n=172; 88 Voranigo; 84 PBO) and astrocytoma (n=159; 80 Voranigo and 79 PBO) were presented at ASCO’23 and published in the NEJM
- Voranigo (40mg Tablets) is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor
Ref: PRNewswire | Image: Servier| Press Release
Related News:- Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
